購物車 
-
Apomine
- names：
tetraisopropyl (2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethane-1,1-diyl)bis(phosphonate)
- CAS號(hào)：
126411-13-0
MDL Number： - MF(分子式)： C28H52O7P2 MW(分子量)： 562.6645
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購物車 立即購買
| 中文別名 | Apomine |
| 英文別名 | Apomine; APB-231-A-2; SK&F-99085; SR-45023A; SR-9223i; APB-231-A2; SK&F99085; SR45023A; SR9223i. |
| CAS號(hào) | 126411-13-0 |
| Inchi | InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3 |
| InchiKey | YLJOVCWVJCDPLN-UHFFFAOYSA-N |
| 分子式 Formula | C28H52O7P2 |
| 分子量 Molecular Weight | 562.6645 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲(chǔ)藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說明 | Apomine(CAS:126411-13-0):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Apomine, also known as APB-231-A-2; SK&F-99085; SR-45023A; SR-9223i, is an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Apomine accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Ang ZY, Boddy M, Liu Y, Sunderland B. Stability of apomorphine in solutions containing selected antioxidant agents. Drug Des Devel Ther. 2016 Oct 3;10:3253-3265. PubMed PMID: 27757015. |
| [2]Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012 Feb 1;118(3):750-60. doi: 10.1002/cncr.26336. PubMed PMID: 21751201. |
| [3] Kuehl PJ, Stratton SP, Powell MB, Myrdal PB. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. PubMed PMID: 19699284; PubMed Central PMCID: PMC2783960. |
| [4] Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther. 2007 Jul;322(1):228-35. PubMed PMID: 17412884; PubMed Central PMCID: PMC2820734. |
| [5] Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007 Apr 15;120(8):1657-63. PubMed PMID: 17230522. |
6: Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs. 2007 Apr;25(2):107-14. PubMed PMID: 17024575.7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.8: Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan;24(1):89-94. PubMed PMID: 16379038.9: Kuehl PJ, Angersbach BS, Stratton SP, Myrdal PB. Development of an HPLC method for the analysis of Apomine in a topical cream formulation. J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80. PubMed PMID: 16181759.10: Elmore E, Siddiqui S, Navidi M, Steele VE, Redpath JL. Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. J Cell Biochem. 2005 Jun 1;95(3):571-88. PubMed PMID: 15786488.1
對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
